Navigation Links
Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2010 Financial Results
Date:7/22/2010

SAN DIEGO, July 22 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2010 financial results after the Nasdaq market closes on Wednesday, July 28, 2010.  Neurocrine will then host a  live conference call and webcast to discuss its financial results and provide a Company update Thursday morning, July 29, 2010 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time).

Participants can access the live conference call by dialing 1-800-894-5910, (US) or 785-424-1052 (International) using the conference ID: 7NBIX. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com.  If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600.  A replay of the Conference Call will be available approximately one hour after the conclusion of the call by dialing 1-800-753-5207 (US) or 402-220-2156 (International) using the conference ID: 7NBIX. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Neurocrine Biosciences Presents Elagolix Data
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
8. Neurocrine Biosciences Reports Third Quarter 2009 Results
9. Neurocrine Advances VMAT2 Inhibitor Program
10. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Neurocrine Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... NEW YORK , Feb. 22, 2017 /PRNewswire/ ... dominate medical implant demand, as aging demographic patterns ... heart-related conditions. Implants for sports- and exercise-related injuries, ... artery disease will lead sales gains. The future ... The study addresses the following questions and more: ...
(Date:2/23/2017)... Ill. , Feb. 23, 2017 Takeda ... subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) and Cognition ... PLC and Ctrl Group Limited, announced a collaboration to ... an Apple Watch wearable to monitor and assess cognitive ... Depression (MDD) is the leading cause of disability ...
(Date:2/23/2017)... 22, 2017 Mixed tocopherols market projected to grow ... market is projected to reach USD 5.27 billion by 2022, ... driven by factors such as health and wellness trends, for ... and regulations for sourcing, processing, packaging, and labeling of food ... markets such as the Asia-Pacific region ...
Breaking Medicine Technology:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... Carlos ... problems. He has also continued to spiritually evolve, which is the purpose of everyone ... “ Our Spiritual Truths ” (published by Balboa Press) attempts to guide readers to ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem cell therapy has ... technology is so cutting edge, in fact, the U.S. Food and Drug Administration ... However, successful patient outcomes in certain clinical stem cell procedures have shown that ...
(Date:2/22/2017)... ... February 22, 2017 , ... South Bend’s Lunkerville, the award-winning TV ... feature Heroes On The Water (HOW), a non-profit organization dedicated to helping military veterans ... series host ‘Mike D’ traveling to Lake Denmark, New Jersey, to fish with war ...
(Date:2/22/2017)... Jacksonville, Fla. (PRWEB) , ... February 22, 2017 ... ... aneurysms is just as effective on smaller and sometimes harder to reach ones, ... findings were presented at the International Stroke Conference in Houston by Ricardo A. ...
(Date:2/22/2017)... Singapore, Singapore (PRWEB) , ... February 22, 2017 , ... ... high-end medical leads utilizing a simple online checklist. Over a period of just 24 ... with the assistance of an online checklist called T.A.D. , “The internet is not ...
Breaking Medicine News(10 mins):